Vizsgálati helyszín
Care Clinic Sp. Z O.O.
Katowice, 40-568, LengyelországEU-13 felzárkózó országMég nincs intézményhez kötve
- 19futó vizsgálat
- 5lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 24 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis20 vizsgálat
- 2. fázis3 vizsgálat
- 1. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz13 vizsgálat
- Lezárult5 vizsgálat
- Toboroz5 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Incyte Corporation3 vizsgálat
- Novo Nordisk A/S3 vizsgálat
- Alumis Inc2 vizsgálat
- F. Hoffmann-La Roche AG2 vizsgálat
- Hoffmann-La Roche2 vizsgálat
- és még 8
Futó vizsgálatok
Még nem toboroz
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
2025-525022-35-00· 3. fázis· Hunan Mabgeek Biotech Co. Ltd.· Forrás
Még nem toboroz
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· 3. fázis· Novo Nordisk A/S· Forrás
Fut, nem toboroz
Study of an On-Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis
2025-523726-40-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Toboroz
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
NCT07503873· 2. fázis· TG Therapeutics, Inc.· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
NCT07220642· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401· 3. fázis· Neurocrine Biosciences· Forrás
Fut, nem toboroz
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· 3. fázis· Incyte Corporation· Forrás
Toboroz
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06786624· 3. fázis· Neurocrine Biosciences· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· 3. fázis· Alumis Inc· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases
2023-509555-13-00· 1. fázis· Tg Therapeutics Inc.· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.
NCT05636176· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
NCT05399888· 2. fázis· Biogen· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
NCT04130997· 3. fázis· TG Therapeutics, Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek